File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

TitleFour years of lamivudine treatment in Chinese patients with chronic hepatitis B
Authors
Issue Date2004
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 2004, v. 19 n. 11, p. 1276-1282 How to Cite?
AbstractBackground and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine treatment and the clinical relevance of the emergence of YMDD-variant hepatitis B virus (HBV). Methods: Fifty-eight Chinese adult patients with chronic hepatitis B (CHB) were randomized to lamivudine 100 mg/day for up to 5 years and were monitored for YMDD-variant HBV, hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and detectable antibody to HBeAg) and serum alanine aminotransferase (ALT) concentrations. Four-year data are reported here. Results: The rate of HBeAg seroconversion increased with extended therapy and also with higher baseline ALT concentrations. YMDD-variant HBV was detected in 67% (39/58) of patients at some point during treatment. After 4 years, a total of 47% (27/58) of patients achieved HBeAg seroconversion. Thirty-three per cent (13/39) of patients with YMDD-variant HBV achieved HBeAg seroconversion; this increased to 57% (8/14) in patients with moderately elevated (>2-5 × upper limit of normal) pre-treatment ALT concentrations. The proportion of patients that achieved normal serum ALT increased from 29% (17/58) at baseline to 69% (31/45) following 4 years of treatment. That included 68% (23/34) of patients with YMDD-variant HBV and 73% (8/11) of those without the variant. All patients receiving lamivudine had reduced serum concentrations of HBV-DNA compared with baseline, despite the emergence of YMDD-variant HBV in 39 patients. Lamivudine was generally well tolerated; there was little change in the number or type of drug-related adverse events in the fourth year of the study. Conclusions: Despite the emergence of YMDD-variant HBV, Chinese patients showed increased HBeAg seroconversion and improvement in ALT levels with an increased duration of treatment with lamivudine. © 2004 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/76303
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChang, TTen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorChien, RNen_HK
dc.contributor.authorGuan, Ren_HK
dc.contributor.authorLim, SGen_HK
dc.contributor.authorLee, CMen_HK
dc.contributor.authorNg, KYen_HK
dc.contributor.authorNicholls, GJen_HK
dc.contributor.authorDent, JCen_HK
dc.contributor.authorLeung, NWYen_HK
dc.date.accessioned2010-09-06T07:19:48Z-
dc.date.available2010-09-06T07:19:48Z-
dc.date.issued2004en_HK
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 2004, v. 19 n. 11, p. 1276-1282en_HK
dc.identifier.issn0815-9319en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76303-
dc.description.abstractBackground and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine treatment and the clinical relevance of the emergence of YMDD-variant hepatitis B virus (HBV). Methods: Fifty-eight Chinese adult patients with chronic hepatitis B (CHB) were randomized to lamivudine 100 mg/day for up to 5 years and were monitored for YMDD-variant HBV, hepatitis B e antigen (HBeAg) seroconversion (loss of HBeAg and detectable antibody to HBeAg) and serum alanine aminotransferase (ALT) concentrations. Four-year data are reported here. Results: The rate of HBeAg seroconversion increased with extended therapy and also with higher baseline ALT concentrations. YMDD-variant HBV was detected in 67% (39/58) of patients at some point during treatment. After 4 years, a total of 47% (27/58) of patients achieved HBeAg seroconversion. Thirty-three per cent (13/39) of patients with YMDD-variant HBV achieved HBeAg seroconversion; this increased to 57% (8/14) in patients with moderately elevated (>2-5 × upper limit of normal) pre-treatment ALT concentrations. The proportion of patients that achieved normal serum ALT increased from 29% (17/58) at baseline to 69% (31/45) following 4 years of treatment. That included 68% (23/34) of patients with YMDD-variant HBV and 73% (8/11) of those without the variant. All patients receiving lamivudine had reduced serum concentrations of HBV-DNA compared with baseline, despite the emergence of YMDD-variant HBV in 39 patients. Lamivudine was generally well tolerated; there was little change in the number or type of drug-related adverse events in the fourth year of the study. Conclusions: Despite the emergence of YMDD-variant HBV, Chinese patients showed increased HBeAg seroconversion and improvement in ALT levels with an increased duration of treatment with lamivudine. © 2004 Blackwell Publishing Asia Pty Ltd.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_HK
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAlanine Transaminase - blooden_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHepatitis B Antibodies - blooden_HK
dc.subject.meshHepatitis B Surface Antigens - blooden_HK
dc.subject.meshHepatitis B e Antigens - blooden_HK
dc.subject.meshHepatitis B virus - genetics - immunologyen_HK
dc.subject.meshHepatitis B, Chronic - blood - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleFour years of lamivudine treatment in Chinese patients with chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0815-9319&volume=19&spage=1276&epage=1282&date=2004&atitle=Four+Years+of+Lamivudine+Treatment+in+Chinese+Patients+with+Chronic+Hepatitis+B.en_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1746.2004.03428.xen_HK
dc.identifier.pmid15482535-
dc.identifier.scopuseid_2-s2.0-8344277996en_HK
dc.identifier.hkuros97682en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-8344277996&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume19en_HK
dc.identifier.issue11en_HK
dc.identifier.spage1276en_HK
dc.identifier.epage1282en_HK
dc.identifier.isiWOS:000225063000009-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridChang, TT=7404725147en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridChien, RN=12787728600en_HK
dc.identifier.scopusauthoridGuan, R=7102456913en_HK
dc.identifier.scopusauthoridLim, SG=7404081127en_HK
dc.identifier.scopusauthoridLee, CM=24543421500en_HK
dc.identifier.scopusauthoridNg, KY=7403178546en_HK
dc.identifier.scopusauthoridNicholls, GJ=7006324757en_HK
dc.identifier.scopusauthoridDent, JC=7201577625en_HK
dc.identifier.scopusauthoridLeung, NWY=26643107200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats